Company intelligence / Profile preview

WUND Healing BioPharmaceuticals

Herzliya, Israel

Ownership: Private
Development stage: Other

Overview

WUND Healing BioPharmaceuticals is a clinical-stage biotechnology company focused on the development of advanced therapeutics for chronic wound care. The company's primary focus is on diabetic foot ulcers (DFU), a major complication of diabetes that often leads to amputation. Its lead product, WUND-101, is a topical small-molecule treatment designed to overcome the hypoxic environment of chronic wounds and stimulate the natural healing process. WUND Healing aims to provide effective, easy-to-use solutions that improve patient outcomes and reduce the economic burden of chronic wound management.

Therapeutic areas: CardiovascularEndocrinologyDermatology
Modalities: Small moleculeTopical formulation
Industry: Biotech

Beyond the preview

Go deeper on WUND Healing BioPharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WUND Healing BioPharmaceuticals.

Explore the full profile